Book a demo
Skip to content

Stonewake Monitoring

BioXcel Therapeutics files 8-K covering debt obligation and Nasdaq notices

The pharmaceutical company filed a Form 8-K on September 1, 2026, days after a bankruptcy filing was recorded.

Export financeUSAPublished · 3 sourced facts

BioXcel Therapeutics, Inc., a pharmaceutical preparations company incorporated in Delaware and listed on Nasdaq under the ticker BTAI, filed a Form 8-K on September 1, 2026.[1][2]

The filing, submitted under accession number 0001104659-26-104106, covers Item 2.03 and Item 3.01 and carries a period ending August 31, 2026.[1]

The filing relates to a debt obligation event dated September 1, 2026, according to the SEC EDGAR debt record.[1]

A prior event of type bankruptcy filed is recorded for the company with a date of August 28, 2026.[3]

Sources

  1. [1]SEC EDGAR: 8-K, 0001104659-26-104106, 1 Sep 2026
  2. [2]SEC EDGAR: CIK 0001720893, BioXcel Therapeutics, Inc.
  3. [3]SEC EDGAR

SEC EDGAR

← All briefs